Basket | Login | Register


Reviewers rate PredictND progress as excellent

Tuesday 14 March 2017

On 14 March 2017, the PredictND team attended an interim review meeting with the European Commission and the review board to present the progress and achievements of the project.

The objectives of the project are to develop a clinical protocol for enabling earlier and objective differential diagnostics of neurodegenerative diseases, a low-cost battery of tests for early detection, a clinical protocol for cost efficient differential diagnostics of neurodegenerative diseases utilising these tests and a decision support software tool to be used in clinical workflows for differential diagnostics of neurodegenerative diseases.

The representatives of the different work packages updated the European Commission and the reviewers about the progress since the last review and gave updates on the overall progress (Mark van Gils, VTT, Finland), the clinical data acquisition and management (Hilkka Soininen, University of Eastern Finland, Finland), the decision support tool requirements (Timo Urhemaa, VTT, Finland and Jan Wolber, GE Healthcare, UK), the biomarker discovery tools (Daniel Rueckert, Imperial College, UK), the clinical validation studies (Steen Hasselbalch, Rigshospitalet, Denmark) and the business development and dissemination activities (Lennart Thurfjell, Combinostics, Finland). Hanneke Rhodius-Meester (VUMC, Netherlands) gave a demonstration of the developed decision support tool to show how the tool can be used by clinicians and Jyrkie Lötjönen (Combinostics, Finland) updated the reviewers on how the team had addressed the comments of the reviewers from the last meeting. All of these presentations had been prepared and rehearsed at a project team meeting in Copenhagen, Denmark on 6 and 7 March 2017.

The reviewers showed a lot of interest in the different achievements with a number of lively question and answer sessions following the different presentations. All in all, the reviewers were impressed by the progress to date which they rated as “excellent”.

Alzheimer Europe supports the dissemination activities of this project and was represented by Jean Georges at the review meeting and by Dianne Gove and Jean at the project team earlier in the month.

NDs are typically diagnosed with a consensus of several experts that have examined the patient and the collected data. The diagnosis will be based on the current guidelines and expertise of the participating specialists. Objective exploitation of data collected from previous patients with similar symptoms is hard. Knowledge of these patients, their tests and outcome should be collected and documented in an intuitive and easy to use form.

Our first technical objective is to develop a decision support software tool to be used in clinical workflows for differential diagnostics of neurodegenerative diseases.

This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 611005.